OctoPlus appoints ceo

Jan Hendrik Egberts to replace Simon Sturge

Dutch drug delivery company OctoPlus has hired Jan Hendrik Egberts and nominated him for appointment as chief executive at its AGM next spring. He will replace current ceo Simon Sturge, who will leave the company on 1 January 2011 to lead a division in a top 15 pharmaceutical company. Egberts will immediately start working with Sturge until the end of this year to ensure a smooth transition.

‘The Board nominates Dr Egberts based on his successful track record in general management, investment management and business development, which he obtained at leading innovative and publicly listed companies,’ said Hans Stellingsma, chairman of OctoPlus.

‘We are sorry to see Simon go but we understand his decision to act on a unique job opportunity.’

Egberts will bring more than 20 years of experience in the pharmaceutical sector to OctoPlus. Most recently he was senior advisor in healthcare investments to private equity firm 3i Group.

You may also like

Drug Delivery

Dr. Reddy’s Laboratories to acquire OctoPlus for €27.4m

Aims to build a research base in Leiden, The Netherlands
Manufacturing

OctoPlus signs agreement with pharma company to develop controlled release formulation

Of a therapeutic compound for local delivery into joints
Manufacturing

Octoplus extends drug delivery contract with Top-5 pharma company

Will combine product candidate with Octoplus PolyActive drug delivery technology
Research & Development

OctoPlus extends development agreement with ESBATech

For controlled release product for ophthalmic indications
Drug Delivery

OctoPlus signs controlled release technology deal with US firm

Will use PolyActive technology to develop compound
Drug Delivery

OctoPlus wins drug delivery contract expansion

Client will proceed with PolyActive technology evaluation
Manufacturing

Continuous innovation: redefining the future of pharmaceutical manufacturing

In an industry in which reliability is paramount and change can be slow, GEA has consistently proven that innovation and stability go hand in hand. Almost two decades ago, GEA introduced the first ConsiGma® continuous manufacturing (CM) system to the pharmaceutical market — a pioneering move that helped to reshape how oral solid dosage (OSD) forms are developed and produced
Subscribe now